Labcorp acquires BioReference Health assets
Article excerpt
Highlighted: the sentence this signal was extracted from
The deal centers on BioReference's laboratory testing operations focused on clinical and women's health testing, urology, and corrections services, along with certain operational assets. Included in the transaction are more than 80 additional patient service centers that will become part of Labcorp's network. A notable component of the acquisition is BioReference's proprietary 4Kscore Test. It is a US Food and Drug Administration ( FDA)-approved blood test designed to help predict the likelihood of finding aggressive prostate cancer before a patient undergoes a biopsy. Labcorp executives said the acquisition would extend the reach of this diagnostic tool and other specialty testing capabilities to a broader population of patients and providers across the country. Financial terms of the agreement set the purchase price at $722 million in cash at closing. This is subject to upward or downward adjustment depending on closing business revenues. An additional earnout of up to $150 million is tied to revenue generated from the 4Kscore Test. Labcorp has projected that the acquired business will generate approximately $250 million in revenue during the first year following the close of the deal, based on its current post-closing forecasts. Related: Labcorp teams with Hawthorne Effect on decentralized trials "This acquisition strengthens our ability to deliver affordable...
Keep reading with a free account
The rest of this article, and every signal for Labcorp, is in your free account.
